Testing DS010 for Cancer-Related Weight Loss
Part of Cancer clinical trials.
This study tests a new medicine called DS010 to help patients with cancer cachexia—severe weight loss and muscle wasting caused by cancer. Researchers want to see if this treatment is safe and helps patients maintain weight and strength.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have a confirmed solid tumor (cancer diagnosed by biopsy or cell sample)
- You have documented cancer cachexia (severe weight and muscle loss from cancer)
- Your overall health status is good enough for treatment (ECOG score 0, 1, or 2)
- You are not currently on tube feeding or IV nutrition support
- You have not had severe allergic reactions to monoclonal antibody medicines (lab-made proteins used as treatments)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a new drug (AV-380) in people with solid tumor cancer who are losing weight and muscle because of cancer. It mainly helps researchers find a safe dose and see how the body responds, and it may offer a new option for cancer-related cachexia.
This trial tests a “multimodal” program meant to help people with cancer avoid developing cachexia, a condition that causes unwanted weight and muscle loss. It may help you stay stronger and maintain weight if you are not yet in advanced or rapidly worsening stages.
This trial looks at how well patient-recorded measurements can be used during cancer care around the time of curative-intent surgery or chemotherapy before surgery. It may help improve monitoring and decision-making during treatment.
This study tests a new medicine (QLS2319) to see if it’s safe and can help people with cancer-related weight loss and muscle loss (cachexia). It’s for people whose daily activities aren’t severely limited by their cancer.
This study tests a new drug called GFS202A for people with advanced solid tumors who are experiencing weight loss or have a low body mass index (cachexia). The goal is to see if the drug is safe and can help improve appetite and weight.
This trial tests a new drug, ASCA101, for people with certain cancers who are experiencing unwanted weight loss (cachexia). It aims to see if the drug can help improve appetite and stabilize weight. Participants must have colorectal, ovarian, or lung cancer and meet specific weight loss criteria.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.